Mersana Therapeutics to Host Fourth Quarter and Year End 2023 Conference Call on February 28, 2024

Rhea-AI Summary

Mersana Therapeutics, a clinical-stage biopharmaceutical company, will report its Q4 and full-year financial results on February 28, 2024. The company focuses on developing antibody-drug conjugates for cancer treatment.

CAMBRIDGE, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the fourth quarter and full year ended December 31, 2023 on Wednesday, February 28, 2024. The company will host a conference call and webcast at 8:00 a.m. Eastern Time that morning.

To access the call, please dial 877-270-2148 (domestic) or 412-902-6510 (international). A live webcast of the presentation will be available on the Investors & Media section of the Mersana website at www.mersana.com, and a replay of the webcast will be available in the same location following the conference call for approximately 90 days.

About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel antibody-drug conjugates (ADCs) and driven by the knowledge that patients are waiting for new treatment options. The company has developed proprietary cytotoxic (Dolasynthen) and immunostimulatory (Immunosynthen) ADC platforms that are generating a pipeline of wholly-owned and partnered product candidates with the potential to treat a range of cancers. Its pipeline includes XMT-1660, a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2). Mersana routinely posts information that may be useful to investors on the “Investors & Media” section of its website at www.mersana.com.

Contact:
Jason Fredette
617-498-0020
jason.fredette@mersana.com

FAQ

When will Mersana Therapeutics report its financial results for Q4 and full year 2023?

Mersana Therapeutics will report its financial results for the fourth quarter and full year ended December 31, 2023, on Wednesday, February 28, 2024.

What does Mersana Therapeutics focus on in terms of drug development?

Mersana Therapeutics focuses on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need.

How can investors access the conference call and webcast for Mersana Therapeutics?

Investors can access the conference call and webcast by dialing 877-270-2148 (domestic) or 412-902-6510 (international). A live webcast will also be available on the Investors & Media section of the Mersana website at www.mersana.com.